An umbrella review of Lianhua Qingwen combined with Western medicine for the treatment of coronavirus disease 2019

作者：Kelu Yang, Jiaoyan Zhang, Liang Zhao, Luying Cheng, Yuanyuan Li, Yuchen Kang, Xiangyu Zhang, Yingying Kang · 发表于：Acupuncture and Herbal Medicine · 年份：2022 · DOI：10.1097/hm9.0000000000000041 · 被引用次数：14 · 研究领域：Meta-analysis and systematic reviews、Traditional Chinese Medicine Studies、COVID-19 Clinical Research Studies

Objective: Lianhua Qingwen combined with Western medicine (LHQW+WM) has been proposed as a viable treatment for coronavirus disease 2019 (COVID-19). Interestingly, umbrella reviews of systematic reviews (SRs), which provide the most comprehensive evidence, are the best evidence in evidence-based medicine. Therefore, an umbrella review of SRs that summarizes and evaluates the efficacy of LHQW+WM for COVID-19 is urgently required. Methods: Overall, 6 databases were used to conduct a comprehensive literature search from inception to January 22, 2022. The corrected covered area (CCA) was used to analyze the overlapping between SRs. Meta-analysis was conducted when that of the included SRs was inappropriate. A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) was also employed to assess the quality of the included SRs. Results: In total, 12 SRs were identified, which included 12 unique primary studies. The included SRs ranged in quality from moderate to critically low and had an extremely high CCA (36.4%). Compared to conventional treatment, LHQW+WM showed efficacy concerning fatigue recovery [risk ratio ( RR ) = 1.69, 95% confidence interval ( CI ): 1.04–2.73, n = 2, I 2 = 0%], cough recovery ( RR = 1.65, 95% CI : 1.09–2.51, n = 3, I 2 = 39.1%), and overall effective rates ( RR = 1.17, 95% CI : 1.07–1.28, n = 3, I 2 = 17.5%). Conclusion: LHQW+WM may improve the clinical symptoms of patients with COVID-19; however, the results should be interpreted cautiously because of the...